119 related articles for article (PubMed ID: 27039388)
1. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
Faissner S; Nikolayczik J; Chan A; Hellwig K; Gold R; Yoon MS; Haghikia A
J Neurol; 2016 Jun; 263(6):1092-8. PubMed ID: 27039388
[TBL] [Abstract][Full Text] [Related]
2. The Utility of Miniaturized Adsorbers in Exploring the Cellular and Molecular Effects of Blood Purification: A Pilot Study with a Focus on Immunoadsorption in Multiple Sclerosis.
Körtge A; Breitrück A; Doß S; Hofrichter J; Nelz SC; Krüsemann H; Wasserkort R; Fitzner B; Hecker M; Mitzner S; Zettl UK
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473836
[TBL] [Abstract][Full Text] [Related]
3. Outcome of MS relapses in the era of disease-modifying therapy.
Stoppe M; Busch M; Krizek L; Then Bergh F
BMC Neurol; 2017 Aug; 17(1):151. PubMed ID: 28784102
[TBL] [Abstract][Full Text] [Related]
4. Contribution of different relapse phenotypes to disability in multiple sclerosis.
Stewart T; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Duquette P; Girard M; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Shaygannejad V; Hupperts R; Alroughani R; Oreja-Guevara C; Pucci E; Boz C; Lechner-Scott J; Bergamaschi R; Van Pesch V; Iuliano G; Ramo C; Taylor B; Slee M; Spitaleri D; Granella F; Verheul F; McCombe P; Hodgkinson S; Amato MP; Vucic S; Gray O; Cristiano E; Barnett M; Sanchez Menoyo JL; van Munster E; Saladino ML; Olascoaga J; Prevost J; Deri N; Shaw C; Singhal B; Moore F; Rozsa C; Shuey N; Skibina O; Kister I; Petkovska-Boskova T; Ampapa R; Kermode A; Butzkueven H; Jokubaitis V; Kalincik T;
Mult Scler; 2017 Feb; 23(2):266-276. PubMed ID: 27055805
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review.
McKay KA; Jahanfar S; Duggan T; Tkachuk S; Tremlett H
Neurotoxicology; 2017 Jul; 61():189-212. PubMed ID: 27045883
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological changes of inflammatory syndrome in multiple sclerosis after instituting therapeutic plasmapheresis.
Vlaic S; Poalelungi V; Bălăeţ M; Purcărea VL; Bălăeţ C; Coculescu BI
J Med Life; 2017; 10(1):50-53. PubMed ID: 28255377
[TBL] [Abstract][Full Text] [Related]
7. Multiple Sclerosis and Antibodies against KIR4.1.
Pröbstel AK; Kuhle J; Lecourt AC; Vock I; Sanderson NS; Kappos L; Derfuss T
N Engl J Med; 2016 Apr; 374(15):1496-8. PubMed ID: 27074084
[No Abstract] [Full Text] [Related]
8. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
[TBL] [Abstract][Full Text] [Related]
9. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
10. A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.
Westerlind H; Stawiarz L; Fink K; Hillert J; Manouchehrinia A
Mult Scler; 2016 Jul; 22(8):1071-9. PubMed ID: 27072687
[TBL] [Abstract][Full Text] [Related]
11. Relapses in multiple sclerosis: Relationship to disability.
Goodin DS; Reder AT; Bermel RA; Cutter GR; Fox RJ; John GR; Lublin FD; Lucchinetti CF; Miller AE; Pelletier D; Racke MK; Trapp BD; Vartanian T; Waubant E
Mult Scler Relat Disord; 2016 Mar; 6():10-20. PubMed ID: 27063617
[TBL] [Abstract][Full Text] [Related]
12. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
Uher T; Vaneckova M; Sobisek L; Tyblova M; Seidl Z; Krasensky J; Ramasamy D; Zivadinov R; Havrdova E; Kalincik T; Horakova D
Mult Scler; 2017 Jan; 23(1):51-61. PubMed ID: 27053635
[TBL] [Abstract][Full Text] [Related]
13. Gavin Giovannoni on why time matters in multiple sclerosis.
Giovannoni G
Neurodegener Dis Manag; 2016 Apr; 6(2):77-9. PubMed ID: 27053013
[No Abstract] [Full Text] [Related]
14. The role of global and regional gray matter volume decrease in multiple sclerosis.
Grothe M; Lotze M; Langner S; Dressel A
J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
[TBL] [Abstract][Full Text] [Related]
15. Increased Signal Intensity in the Dentate Nucleus of Patients with Multiple Sclerosis in Comparison with Neuromyelitis Optica Spectrum Disorder after Multiple Doses of Gadolinium Contrast.
Tanaka M; Nakahara K; Kinoshita M
Eur Neurol; 2016; 75(3-4):195-8. PubMed ID: 27054693
[TBL] [Abstract][Full Text] [Related]
16. Rescue Therapy Using Rituximab for Multiple Sclerosis.
Berenguer-Ruiz L; Sempere AP; Gimenez-Martinez J; Gabaldon-Torres L; Tahoces L; Sanchez-Perez R; Diaz-Marin C
Clin Neuropharmacol; 2016; 39(4):178-81. PubMed ID: 27046661
[TBL] [Abstract][Full Text] [Related]
17. Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
McDonnell GV; Bennett A; Rae-Grant A; Bever C
Neurology; 2016 Apr; 86(14):1361. PubMed ID: 27044615
[No Abstract] [Full Text] [Related]
18. Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study.
Fox J; Kraemer M; Schormann T; Dabringhaus A; Hirsch J; Eisele P; Szabo K; Weiss C; Amann M; Weier K; Naegelin Y; Kappos L; Gass A
Int J Mol Sci; 2016 Apr; 17(4):489. PubMed ID: 27043553
[TBL] [Abstract][Full Text] [Related]
19. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
Komori M; Lin YC; Cortese I; Blake A; Ohayon J; Cherup J; Maric D; Kosa P; Wu T; Bielekova B
Ann Clin Transl Neurol; 2016 Mar; 3(3):166-79. PubMed ID: 27042677
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
